Adjuvant chemotherapy strategies

Older adjuvant cytotoxic regimes such as the triplet of doxorubicin, mitomycin and 5-fluorouracil (AMF) for six cycles to treat pancreatic and papillary cancers showed no overall survival advantage beyond two years, although there was a 1 and 2 year relapse-free survival advantage favouring chemotherapy over surgery alone.!7!

In addition to the survival advantage shown ESPAC-1, the Charité Onkologie (C0NK0-001) study!8] published in 2007 demonstrated a survival benefit with adjuvant gemcitabine over surgery alone. Patients with R0 or R1 resections were assigned to observation alone or gemcitabine delivered at 1000mg/ m2/ week (days 1, 8 and 15 of a 28 day cycle) for a total of six cycles. There was a trend toward an improved median overall survival (22.8 vs. 20.2 months p=0.06) as well as a statistically significant improvement in disease-free survival (13.4 vs. 6.9 months p <0.001) over surgery alone. Importantly the rate of 5-year survival was significantly better in those patients receiving adjuvant gemcitabine over observation alone (21% vs. 9%).

In the largest adjuvant pancreatic trial to date, ESPAC-3I9"10] involved 1088 patients with R0-or R1 resected pancreatic adenocarcinoma, randomising patients into either observation alone, 5-FU/LV, or gemcitabine. Notably the 5-FU was delivered as five bolus doses (425mg/m2 with leucovorin 20mg/ m2 days 1-5 of a 28 day cycle) rather than as an infusion. 551 patients received 5-FU and 537 received gemcitabine with treatment for a total of six months. The observational arm was discontinued after the outcome of the C0NK0-001 trial was made available. At a median follow up of 34.2 months after 753 deaths, there was no advantage seen between the intervention arms (23.0 vs. 23.6 months p=0.39). 12 and 24 month survival was 78.5% and 48.1% respectively in those who received 5-FU with 80.1%

and 49.1% respectively in the gemcitabine arm. The side effect profile however favoured gemcitabine in terms of grade 3-4 toxicity and hospitalisation. Grade 3 and 4 mucositis was seen in 10% of patients who received 5-FU (compared with no patients on gemcitabine). Grade 3-4 diarrhoea was also significantly higher in the 5-FU group. The gemcitabine treated group did however experience higher rates of grade 3 and 4 thrombocytopenia, although the absolute risk of this remained small (1.5 vs. 0%) (p=0.003). Quality-of-life was also comparable.

Thus, survival outcomes were not significantly improved by gemcitabine over 5-FU group in ESPAC-3. This outcome differs to that seen in the advanced setting.[13] One reason could be that the 5-FU intensity was greater in ESPAC-3 than that seen in the Burris et al. trial.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment